Rituxan deaths reported to FDA

Share this article:
The deaths of two women being treated with Genentech's Rituxan (rituximab) for systemic lupus erythematosus have been reported to the FDA. The agency is working with the company to obtain additional info and to strengthen the warnings in the product labeling.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.